July/August 2025, Vol 2, No 7

Pembrolizumab (Keytruda; Merck) has received an FDA nod for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 combined positive score (CPS) ≥1, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin after surgery, and then as a single agent. Read More ›

The Department of Veterans Affairs (VA) has been able to “dramatically increase” clinical trial opportunities and participation in recent years, thanks in large part to a joint initiative from the Prostate Cancer Foundation (PCF) and VA, according to data presented at the 2025 ASCO Annual Meeting, held in Chicago, IL, May 30-June 3, 2025, and published simultaneously online. Read More ›